These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2715930)

  • 1. An area function method for calculating the apparent elimination rate constant of a metabolite.
    Cheng HY; Jusko WJ
    J Pharmacokinet Biopharm; 1989 Feb; 17(1):125-30. PubMed ID: 2715930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The area function method for assessing the drug absorption rate in linear systems with zero-order input.
    Cheng H; Jusko WJ
    Pharm Res; 1989 Feb; 6(2):133-9. PubMed ID: 2762213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An initial slope method for model structure: independent estimation of the elimination rate constant of a metabolite.
    Piotrovskii VK
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):311-8. PubMed ID: 1875284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for calculating the mean absorption time of drugs undergoing reversible and first-pass metabolism.
    Cheng H; Shum L
    Biopharm Drug Dispos; 1993 Jan; 14(1):71-9. PubMed ID: 8427946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An area function method for estimating the apparent absorption rate constant.
    Cheng H; Staubus AE; Shum L
    Pharm Res; 1988 Jan; 5(1):57-60. PubMed ID: 3244611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple integrated method for drug and derived metabolite kinetics. An application of the statistical moment theory.
    Chan KK
    Drug Metab Dispos; 1982; 10(5):474-9. PubMed ID: 6183086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.
    Karol MD; Goodrich S
    Pharm Res; 1988 Jun; 5(6):347-51. PubMed ID: 2469080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers.
    Mahar KM; Stier B; Fries M; McCallum SW
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):418-26. PubMed ID: 27137713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of rate constants for isolating a metabolite by a model-independent method].
    Piotrovskiĭ VK
    Biofizika; 1991; 36(5):899-903. PubMed ID: 1799604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1991 Jan; 8(1):25-32. PubMed ID: 2014204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of variation in drug elimination on five methods for assessing zero-order drug absorption rates.
    Cheng HY; Jusko WJ
    Pharm Res; 1990 Jan; 7(1):76-9. PubMed ID: 2300540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of pentopril, a new orally active angiotensin-converting enzyme inhibitor, and its active metabolite in rats.
    Rakhit A; Kochak G; Dotson R; Tipnis V
    J Pharm Sci; 1985 Sep; 74(9):947-52. PubMed ID: 2999376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Area-based estimation of the initial volume of distribution and elimination rate constant following intravenous bolus injection.
    Khor SP; Johnson SL; Mayersohn M
    J Pharm Sci; 1991 Nov; 80(11):1042-50. PubMed ID: 1815055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
    Ding JJ; Jiao Z; Yu YQ; Shi XJ
    Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general model of metabolite kinetics following intravenous and oral administration of the parent drug.
    Weiss M
    Biopharm Drug Dispos; 1988; 9(2):159-76. PubMed ID: 3370305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.
    Farris FF; King FG; Dedrick RL; Litterst CL
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):13-39. PubMed ID: 4040567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for calculating the mean residence times of catenary metabolites.
    Cheng HY
    Biopharm Drug Dispos; 1991 Jul; 12(5):335-42. PubMed ID: 1878530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A versatile computational method for the determination of areas under the curve and moment curve following multidose drug administration.
    Yamashita TS; Lee HL; Reed MD
    Int J Biomed Comput; 1988 Dec; 23(3-4):239-49. PubMed ID: 3225062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.